Fri Dec 20 06:29:45 UTC 2024: ## Aptose Biosciences Granted Nasdaq Listing Extension, Announces Positive Developments
**SAN DIEGO and TORONTO, Dec. 19, 2024** – Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage oncology company, announced today that the Nasdaq Hearings Panel has granted an extension to regain compliance with Nasdaq listing rules. The company must meet two criteria by March 31, 2025: maintain at least $2.5 million in shareholder equity and a minimum $1.00 closing share price for ten consecutive business days.
Aptose’s recent positive developments bolster its chances of meeting these requirements. The company recently completed an $8 million public offering, signed a clinical development agreement with the National Cancer Institute for its lead drug, tuspetinib (for AML and MDS), and presented encouraging clinical data at the American Society of Hematology (ASH) Annual Meeting, supporting tuspetinib’s use in a triplet therapy for newly diagnosed AML patients.
Tuspetinib, an oral kinase inhibitor, shows promise as both a monotherapy and in combination therapies for treating relapsed or refractory acute myeloid leukemia (AML). The company is committed to developing precision medicines for unmet needs in oncology, focusing initially on hematology.
While the company is optimistic, it acknowledges inherent risks in drug development and achieving Nasdaq compliance. These include securing necessary capital, successfully navigating clinical trials, and obtaining regulatory approvals. Investors are cautioned to review the company’s filings for a complete understanding of these risks.
First Piper 